The absence of anti-Covid vaccine AstraZeneca from a delivery plan shared last week by the army has raised questions about the fate of the vaccine. The British manufacturer accounts for a seventh of the country’s vaccine dose orders.
On Sunday, the paper NZZ am Sonntag wrote that the federal government is considering selling or giving away the Swiss quota if market approval continues to be delayed or is eventually denied. The review is dragging on since October because the competent authority, Swissmedic, has requested additional clinical data from a study in the US.
Nora Kronig, who is in charge of vaccine procurement, told the NZZ am Sonntag that the data situation is currently uncertain, which is why AstraZeneca is not listed in the delivery plan. She added that withdrawal from the sales contract is not an option at the moment but said the order would be reexamined if the vaccine fails to get approval.
According to Kronig, Switzerland is not dependent on AstraZeneca doses and the government does not rule out passing on the doses to others if necessary. A spokesperson for AstraZeneca told the paper that the company is ready to swiftly deliver doses to Switzerland as soon as Swissmedic approves the vaccine.
More than 400,000 cross-border commuters now work in Switzerland
This content was published on
More than half of all cross-border commuters were resident in France (around 57%). Large proportions also lived in Italy (23%) and Germany (around 16%).
Amherd and von der Leyen discuss ongoing Swiss-EU negotiations
This content was published on
Swiss President Viola Amherd and EU Commission President Ursula von der Leyen have met and talked about the ongoing negotiations between Bern and Brussels.
This content was published on
One million francs, 34 million euros and around 830 kilos of gold: this is the fortune that two Swiss nationals are accused of having moved across borders for at least four years.
Girls in female-dominated classes earn more later on
This content was published on
At the age of 30, women from school classes with a 55% share of girls earn $350 more per year than women from classes with a 45% share of girls.
This content was published on
Geneva-based luxury goods group Richemont reported a downturn in performance for the first half of its 2024/25 financial year. Both sales and profit declined.
COP29: Swiss NGOs call for strong financial support
This content was published on
Ahead of COP29, Swiss NGOs call for wealthy nations to pay $1,000 billion a year to help other countries solve climate problems.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss sign next vaccine agreement with AstraZeneca
This content was published on
Switzerland signs agreement with British pharma company AstraZeneca to pre-order up to 5.3 million doses of a Covid-19 vaccine under development.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.